Scarica l'app Stockscreener
16.43
0.18%
-0.03
Dopo l'orario di chiusura:
16.42
-0.010
-0.06%
Precedente Chiudi:
$16.46
Aprire:
$16.61
Volume 24 ore:
1.02M
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.83B
Reddito:
$-665.00K
Utile/perdita netta:
$-144.74M
Rapporto P/E:
-10.58
EPS:
-1.5527
Flusso di cassa netto:
$-123.48M
1 W Prestazione:
+0.74%
1M Prestazione:
+9.90%
6M Prestazione:
+24.09%
1 anno Prestazione:
+219.03%
Intervallo 1D:
$15.98
$16.94
Intervallo di 1 settimana:
$15.39
$16.94
Portata 52W:
$4.20
$18.61
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-682-0917
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, TEVA, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
16.43 | 1.83B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-03 | Iniziato | Stifel | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Investors To Get $6.5M In ALS Drug Settlement - Law360
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia - Business Wire
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
MSN Money - MSN
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch - TipRanks
Press Release: Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Amylyx sets May 7 earnings report, 8 a.m. ET webcast - Stock Titan
Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating - marketscreener.com
BofA raises Amylyx Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Nigeria
BofA raises Amylyx Pharmaceuticals stock price target on model updates - Investing.com
Mizuho raises Amylyx stock price target on lower expense outlook By Investing.com - Investing.com India
Mizuho Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Mizuho raises Amylyx stock price target on lower expense outlook - Investing.com
Amylyx Pharmaceuticals Q3 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals, Inc. ($AMLX) Co-CEO and Director 2025 Pay Revealed - Quiver Quantitative
[ARS] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Executive pay, avexitide milestones and 2026 vote at Amylyx (NASDAQ: AMLX) - Stock Titan
AMLX (Amylyx Pharmaceuticals Inc.) reports narrower Q4 2025 loss than estimates, shares climb 3.55 percent on positive investor sentiment.Revenue Per Share - Cổng thông tin điện tử tỉnh Lào Cai
AMLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amylyx (AMLX) Stock Stop Limit Order (-3.24%) 2026-04-20Pro Level Trade Signals - Xã Thanh Hà
Stock Traders Purchase High Volume of Call Options on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals stock hits 52-week high at 17.5 USD By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL), ANI Pharmaceuticals (ANIP) and Amylyx Pharmaceuticals Inc (AMLX) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amylyx Pharmaceuticals stock hits 52-week high at 17.5 USD - Investing.com
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch - Yahoo Finance
Bull Run: What is Amylyx Pharmaceuticals Incs book value per share2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Layoff Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential - TipRanks
A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone - Sahm
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - GuruFocus
Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News - National Today
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):